GPC3 and hepatocellular carcinoma: The median TTR for patients with HCC expressing low levels of GPC3 was 19.2 (95% CI, 13.1–25.3) months, compared with 32 (95% CI, 16.9–47.1) months for patients with HCC expressing high levels of GPC3 (p = 0.004; log-rank test; Figure 4B).